New hope for Hard-to-Treat cancers: ERAS-4001 enters human trials

NCT ID NCT07021898

Recruiting now Disease control Sponsor: Erasca, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and find the best dose, either alone or with other treatments. About 200 adults who have no good standard options left can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITING

Nashville, Tennessee, 32703, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States